New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million ...
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created
Source: eagletribune.com